Evaluation of the Efficacy of Amineptine in a Population of 1,229 Depressed Patients: Results of a Multicenter Study Carried Out by 135 General Practitioners

Monoaminergic‐based Pharmacotherapy for Depression

“…Although amineptine is no longer in use due to its abuse potential, reviewing studies of amineptine in depression is useful for two reasons: (1) such studies further establish an antidepressant role for dopamine and (2) such studies may provide further insights into the potential advantages for agents with predominantly dopaminergic activity in depression. The use of amineptine as an antidepressant is supported by a number of open trials (Boral and Shah, 1989;Paes de Sousa and Tropa, 1989;Scarzella et al, 1985), as well as placebo-controlled trials (Alevizos et al, 1989;Boyer et al, 1999). Amineptine also appears to be as effective as the TCAs (Bornstein, 1979;Lemoine et al, 1981;Mendis et al, 1989;Rampello et al, 1995;Van Amerongen, 1979;Vauterin and Bazot, 1979), the MAOIs (Macher et al, 1992), and the SSRIs (Dalery et al, 1997) in the treatment of depression, and more effective than placebo in preventing depressive relapses (Ferreri et al, 1997).…”

Cardiovascular Diseases and Vital Exhaustion: Longitudinal Study in Russia/Siberia (Who Monica — Psychosocial Program)

“…Some authors believe that the condition of VE develops in population due to long-standing psychosocial problems that are impossible to solve [17,18]. Dopamine is involved in certain response reactions to surrounding events [19] whereas some dopamine reuptake inhibitors exert antidepressant effect [20]. Therefore, the study of genetic traits in VE is of high demand.…”